ASSESSING SIMILARITY OF STUDIES FOR NETWORK META-ANALYSIS: THE USE OF FEASIBILITY ASSESSMENT AND SENSITIVITY ANALYSES TO ESTIMATE THE EFFICACY OF TIRBANIBULIN, A NEW DRUG FOR ACTINIC KERATOSIS

Heppt M, Dykukha , Chapman-Rounds M, Graziadio S, Edwards M (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Value in Health Wiley-Blackwell: No OnlineOpen / Elsevier

Publisher: ELSEVIER SCIENCE INC

City/Town: NEW YORK

Pages Range: S367-S368

Conference Proceedings Title: VALUE IN HEALTH

DOI: 10.1016/j.jval.2022.09.1824

Authors with CRIS profile

Markus Heppt Department of Dermatology

Involved external institutions

Almirall Hermal GmbH DE Germany (DE) York Health Economics Consortium Ltd. (YHEC) GB United Kingdom (GB)

How to cite

APA:

Heppt, M., Dykukha, ., Chapman-Rounds, M., Graziadio, S., & Edwards, M. (2022). ASSESSING SIMILARITY OF STUDIES FOR NETWORK META-ANALYSIS: THE USE OF FEASIBILITY ASSESSMENT AND SENSITIVITY ANALYSES TO ESTIMATE THE EFFICACY OF TIRBANIBULIN, A NEW DRUG FOR ACTINIC KERATOSIS. In VALUE IN HEALTH (pp. S367-S368). NEW YORK: ELSEVIER SCIENCE INC.

MLA:

Heppt, Markus, et al. "ASSESSING SIMILARITY OF STUDIES FOR NETWORK META-ANALYSIS: THE USE OF FEASIBILITY ASSESSMENT AND SENSITIVITY ANALYSES TO ESTIMATE THE EFFICACY OF TIRBANIBULIN, A NEW DRUG FOR ACTINIC KERATOSIS." Proceedings of the VALUE IN HEALTH NEW YORK: ELSEVIER SCIENCE INC, 2022. S367-S368.

BibTeX: Download